💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tisagenlecleucel

CHEMBL3301574 Phase 4 Одобрено Cell
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tisagenlecleucel is an autologous CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19, enabling highly specific T-cell-mediated cytotoxicity against CD19-expressing B-cell malignancies. It is approved for relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients, and for diffuse large B-cell lymphoma. The manufacturing process involves lentiviral transduction of harvested T cells followed by expansion and re-infusion after lymphodepleting chemotherapy.

Терапевтические области

Non-Small Cell Lung Cancer Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Tisagenlecleucel is an autologous CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19, enabling highly specific T-cell-mediated cytotoxicity against CD19-expressing B-cell malignancies. It is approved for relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients, and for diffuse large B-cell lymphoma. The manufacturing process involves lentiviral transduction of harvested T cells followed by expansion and re-infusion after lymphodepleting chemotherapy.

Yes, Tisagenlecleucel is an approved drug. It has reached clinical phase 4. It is classified as a Cell.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301574. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.